Mode
Text Size
Log in / Sign up
Phase 4 N=180 Randomized Double-blind Treatment

Misoprostol Dosing in BMI Greater Than 30

Pregnancy Related · Obesity · Labor Onset and Length Abnormalities

Enrolled (actual)
180
Serious AEs
3.9%
Results posted
Jul 2024
Primary outcome: Primary: Interval Time From Labor Induction Initiation to Delivery (Vaginal or Cesarean) — 18.56; 21.59 hours

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
50 Micrograms Vaginal Misoprostol (Intervention) (Drug); 25 Micrograms Vaginal Misoprostol (Control) (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Texas at Austin
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Interval Time From Labor Induction Initiation to Delivery (Vaginal or Cesarean)
18.56; 21.59
SECONDARY
Interval Time From Labor Induction to Vaginal Delivery
17.20; 19.00
SECONDARY
Number of Cesarean Deliveries
25; 24
SECONDARY
Number of Participants Exhibiting Uterine Tachysystole
20; 9
SECONDARY
Number of Participants Exhibiting Uterine Tachysystole With Fetal Decelerations
2; 2
SECONDARY
Number of Participants Receiving Terbutaline
2; 1
SECONDARY
Number of Participants Diagnosed With Clinical Chorioamnionitis
8; 10
SECONDARY
Number of Participants Diagnosed With Postpartum Hemorrhage
12; 17
SECONDARY
Patient Satisfaction Six Simple Questions, Question 1
6; 6
SECONDARY
Patient Satisfaction Six Simple Questions, Question 2
7; 7
SECONDARY
Patient Satisfaction Six Simple Questions, Question 3
2; 2
SECONDARY
Patient Satisfaction Six Simple Questions, Question 4
6; 7
SECONDARY
Patient Satisfaction Six Simple Questions, Question 5
2; 2
SECONDARY
Patient Satisfaction Six Simple Questions, Question 6
7; 6.5
SECONDARY
Patient Satisfaction (Labor Pain Scale, Question 1)
8; 8
SECONDARY
Patient Satisfaction (Labor Pain Scale, Question 2)
6; 6.5
SECONDARY
Patient Satisfaction (Labor Pain Scale, Question 3)
5; 5
SECONDARY
Patient Satisfaction (Labor Pain Scale, Question 4)
2; 2

Summary

The investigators are performing a randomized controlled-trial investigating if 50mcg (compared to 25 mcg) of vaginal misoprostol reduces the time from induction start to delivery in obese women.

Eligibility Criteria

Inclusion Criteria

  • Singleton gestation
  • Age 18 years or older
  • Gestational age >= 36 weeks
  • BMI >= 30 kg/m2 at time of labor induction
  • Cephalic presentation (including successful external cephalic version)
  • Cervical dilation 3cm
  • No intention to proceed with cervical ripening (not indicated, favorable bishop score, plan for Oxytocin administration, etc.)
  • Uterine tachysystole (defined as >= 5 contractions within a 10m period)
  • Fetal Growth Restriction (EFW <= 5% or elevated/absent/reversed Umbilical Artery dopplers)
  • Inability to give consent (inability to read/write in English or Spanish)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05262738). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search